Uncategorized
European Medicines Agency´s (EMA) Committee for Medicinal Products for Human Use (CHMP), has adopted a positive opinion recommending marketing authorization approval (MAA) of melphalan flufenamide, also called melflufen, a drug commercialised by Oncopeptides with the name of Pepaxti®.
The European Hematology Association’s (EHA) annual congress, one of the most important haematology congresses here in Europe, was held in Vienna, Austria from 9 June to 12 June 2022 in a hybrid format.
Myeloma Patients Europe (MPE) attended EHA 2022 in person and interviewed relevant myeloma and AL amyloidosis specialists to provide an overview of the key highlights in both diseases presented during this meeting.
The European Commission has granted conditional approval to CAR-T cell therapy Carvytki (cilta-cel) for the treatment of relapsed and refractory myeloma.
Myeloma Patients Europe (MPE) held its Annual General Meeting (AGM) on 29 March 2022, where MPE members were invited to discuss present and future MPE projects, vote on the annual budget, and hold board elections. Five members of the current board stepped down either due to reaching the maximum number of terms or for personal reasons: Hans Scheurer, Johannes Brenner and Kristina Modic (first elected in 2016) and Roman Slomkowski (2018) and Nikita E.Shklovskiy-Kordi (2020)
MPE wants to deeply thank these members for their work and commitment during their time of service and their contribution to improving myeloma and AL amyloidosis patients’ lives. Continue reading
A multi-stakeholder coalition consisting of more than 60 representatives from the global patient advocacy and clinical community has formed the International COVID-19 Blood Cancer Coalition (ICBCC) to address the specific impact of the pandemic on immunocompromised blood cancer patients and to recommend solutions and actions to mitigate those risks.
Continue reading
Myeloma Patients Europe (MPE) is here to support Ukrainian patients during this ongoing crisis. If you are a myeloma or AL amyloidosis patient in Ukraine or a refugee in another European country and in need of information on how to access treatment and support, please contact us at info@mpeurope.org. Continue reading
- Job Title: Policy and Public Affairs Officer
- Position Type: Full time/permanent
- Location: Brussels, Belgium
- Travel required: 30 days / year (approx.)
- Gross salary: 35,000 – 40,000 EUR/year
The world’s largest haematology conference will be held in person and virtually this year from the 11th to 14th of December. Despite the continued difficulties and limitations posed by the coronavirus pandemic, this year’s American Society of Haematology Annual Meeting will feature, more than 200 abstracts in myeloma and AL amyloidosis. Continue reading
Myeloma Patients Europe (MPE) is seeking research grant applications, for funding of up to 100k €, on a project exploring shared-decision making in myeloma.
If you are interested, please read the information below and complete the following application form. Deadline for submission is 3 pm CET on Friday 5th of November 2021
Myeloma Patients Europe (MPE) will hold a webinar to review the most recent updates on the approved COVID-19 vaccines in Europe and how they affect myeloma and AL amyloidosis patients. Continue reading